News Release

Nearly half of public wrongly believe heart failure is normal in old age

Peer-Reviewed Publication

European Society of Cardiology

Low awareness of heart failure among patients and the public is highlighted in surveys to be presented during Heart Failure 2019 the annual congress of the Heart Failure Association (HFA), a branch of the European Society of Cardiology (ESC), taking place in Athens, Greece from 25 to 28 May.

Today's preview, on Heart Failure Awareness Day, reveals other myths about heart failure: one in five members of the public said patients should avoid exercise, while just over half of patients knew that exercise can be a treatment for their disease. Tips for patients on living with heart failure can be found on the Heart Failure Matters website.

The HFA is set to launch the Heart Failure Atlas which maps disparities in prevention and treatment across ESC member countries. Congress attendees will get the first look in Athens.

Novel research on many heart failure topics will be presented during the event in 1,700 abstracts, including:

  • In vitro fertilisation: linked to heart failure?
  • You are what you eat: diet, gut microbes, and heart failure outcomes.
  • How yogic breathing is being used in chronic heart failure.
  • What determines who follows heart failure treatment advice, and who doesn't?
  • How machine learning could help select patients for cardiac resynchronisation therapy.
  • Predicting recovery of ejection fraction in heart failure patients.
  • Do women and men need different doses of heart failure drugs?
  • An innovative non-invasive biomarker to detect heart transplant rejection.

Explore the scientific programme for Heart Failure 2019 and the World Congress on Acute Heart Failure. To be held 25 to 28 May at the Megaron Athens International Conference Centre.

Four late breaking trial sessions 1 on acute and chronic heart failure, innovative treatments, device therapies and registries will showcase cutting edge findings, among them:

  • PHARM-CHF randomised controlled trial on improving adherence to heart failure medications.
  • ReBIC-1 randomised trial on the safety of diuretic withdrawal in chronic heart failure patients.
  • Can activity of the adrenomedullin system be used to personalise acute heart failure treatment?
  • First-in-human research: DSR-FIH study of direct sodium removal and VECTOR-HF study of a novel battery-free and wireless pressure monitor.

The world's leading heart failure congress will attract around 6,000 cardiologists, cardiac nurses, surgeons, general physicians, basic scientists, and epidemiologists from over 100 countries. The latest advances in prevention and treatment will be discussed in more than 175 sessions across four days.

Technology update: Mobile applications for heart failure management, and the role of social media.2 Plus the use of big data, artificial intelligence, and wearable devices for monitoring patients with heart failure.3

Featured presentations: Are cancer and heart failure enemies in treatment?4 Leaders in the field take a look at whether heart failure promotes cancer or vice versa, common pathways in tumour growth and heart failure, which cancer therapies are toxic to the heart,5 and molecular strategies to combat cardiotoxicity.

Not to miss: Emerging drugs and devices in heart failure.6-10 Of particular interest: What is different about heart failure in women?11 Also on the agenda: Developments in lifestyle including alcohol, tobacco, diet, weight control, sodium restriction, exercise, and sex life.12

The congress theme is: "Heart failure: from alpha to omega". Professor Gerasimos Filippatos, scientific chair, said: "Based on the first and last letters of the Greek alphabet, the theme illustrates that the meeting will cover the entire heart failure journey, from prevention through to palliative and end of life care."

###

Authors: ESC Press Office
Tel: +33 (0)4 8987 2499
Mobile: +33 (0)7 8531 2036
Email: press@escardio.org
Follow us on Twitter @ESCardioNews

Notes to editor

The hashtag for Heart Failure 2019 and the World Congress on Acute Heart Failure is #heartfailure2019.

References and notes

    1. Late breaking trial sessions.

    2. E-health and social media in heart failure.

    3. The future of big data strategies in heart failure.

    4. Cancer and heart failure: enemies in treatment?

    5. Special issues in cardio-oncology.

    6. Heart failure innovation - Drugs, devices, artificial intelligence.

    7. Emerging therapies in heart failure.

    8. Upcoming and novel drugs in heart failure.

    9. Parade of devices 1: attend and learn.

    10. Parade of devices 2: attend and learn.

    11. Female heart failure; what is different?

    12. Lifestyle interventions in chronic heart failure.

About Heart Failure and the World Congress on Acute Heart Failure

Heart Failure and the World Congress on Acute Heart Failure are annual congresses of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

About the Heart Failure Association

The Heart Failure Association (HFA) is a branch of the European Society of Cardiology (ESC). Its aim is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

Information for journalists attending Heart Failure 2019

Heart Failure 2019 and the World Congress on Acute Heart Failure will be held 25 to 28 May at the Megaron Athens International Conference Centre in Greece. Explore the scientific programme.

  • Free registration applies to accredited press.
  • Credentials: A valid press card or appropriate letter of assignment with proof of three recent published articles (cardiology or health-related, or referring to a previous ESC Event). Read the ESC media and embargo policy.
  • The ESC Press Office will verify the documents and confirm by email that your press accreditation is valid.
  • The decision of the ESC Press Office is final regarding all press registration requests.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.